Personalized approach to immune system rehabilitation in patients with year-round allergic rhinitis suffering from recurrent ARVI and recurrent herpes virus infections
- Authors: Khalturina E.O.1,2, Garskova N.V.3,2, Shemetova A.D.1
-
Affiliations:
- I.M. Sechenov First Moscow State Medical University (Sechenov University)
- MEDSI Clinical Diagnostic Center at Belorusskaya
- Academy of Postgraduate Education of the Federal Research and Clinical Centre FMBA of Russia
- Issue: Vol 14, No 3 (2024)
- Pages: 623-631
- Section: SHORT COMMUNICATIONS
- URL: https://journal-vniispk.ru/2220-7619/article/view/262090
- DOI: https://doi.org/10.15789/2220-7619-PAT-16826
- ID: 262090
Cite item
Full Text
Abstract
Introduction. The problem of treating patients with respiratory allergopathology associated with recurrent infectious diseases, such as rARVI, frequent exacerbations of rCHVI, is becoming urgent. The presence of persistent inflammation and co-infection significantly complicates the treatment of immunocompromised patients with year-round allergic rhinitis (YAR) and necessitates the development of personalized programs, with the inclusion of immunomodulatory agents for restoring disorders in the immune system (IS) and interferon system (IFN). Materials and methods. The study group (SG) included 65 patients of both sexes aged 23–60 years, suffering from YAR associated with rARVI and rCHVI. The comparison group (CG) consisted of 50 healthy individuals, comparable in sex and age. All patients underwent standard physical, immunological and allergological examinations, including the use of serological (ELISA, ImmunoCUP), molecular genetic (PCR-RV) methods, FC, etc. Voluntary informed consent was obtained from all patients. The StatPlus computer program was used for statistical analysis. Results and discussion. In patients with YAR associated with rARVI and rCHVI, two variants of disorders in IS have been established, which are defined as pathological immunophenotypes (PIF). The PIF1 is characterized by a deficiency in the induced production of IFNα, a decrease in CD3⁻CD16⁺CD56+ EKKs, and a decrease in neutrophil granulocytes (NG). In the PIF2, along with a shortage of IFNα production, a decrease in EKKs is observed in combination with a decrease in CTLs, as well as a decrease in NGs. The clinical criteria for immunocompromising in this cohort of patients were studied. The severity of YAR symptoms was assessed by VAS. In order to correct the identified disorders in the IS and IFN system, complex personified IFN- and immunotherapy programs have been developed for each PIF, including prolonged local and systemic therapy with rIFNα2b in combination with antioxidants, as well as GMDP for patients of SG1, and for patients of SG2 — GMDP and hexapeptide. The high immunological and clinical efficacy of IFN- and immunotherapy was shown, which was expressed in the tendency to restore existing disorders, as well as in achieving control over the symptoms of YAR, with the possibility of reducing the volume of basic antiallergic pharmacotherapy.
Full Text
##article.viewOnOriginalSite##About the authors
Evgeniya O. Khalturina
I.M. Sechenov First Moscow State Medical University (Sechenov University); MEDSI Clinical Diagnostic Center at Belorusskaya
Author for correspondence.
Email: jane_k@inbox.ru
DSc (Medicine), Professor of the Department of Microbiology, Virology and Immunology named after A.A. Vorobiev, Allergist-Immunologist in Clinical Diagnostic Center “Medsi on Belorusskaya”
Russian Federation, Moscow; MoscowN. V. Garskova
Academy of Postgraduate Education of the Federal Research and Clinical Centre FMBA of Russia; MEDSI Clinical Diagnostic Center at Belorusskaya
Email: jane_k@inbox.ru
3rd year PhD Student, Department of Immunopathology and Immunodiagnosis, Academy of Postgraduate Education, Allergist-Immunologist
Russian Federation, Moscow; MoscowA. D. Shemetova
I.M. Sechenov First Moscow State Medical University (Sechenov University)
Email: jane_k@inbox.ru
2nd year Student of Erismann Institute of Public Health
Russian Federation, MoscowReferences
- Маркова Т.П., Чувиров Д.Г., Ярилина Л.Г., Чувирова А.Г., Шадыжева М.Б., Аршинова С.С. Аллергический ринит и коморбидность c инфекциями // Эффективная фармакотерапия. 2023. Т. 19, № 32. С. 8–14. [Markova T.P., Chuvirov D.G., Yarilina L.G., Chuvirova A.G., Shadyzheva M.B., Arshinova S.S. Allergic rhinitis and comorbidity with infections. Effektivnaya farmakoterapiya = Effective Pharmacotherapy, 2023, vol. 19, no. 32, pp. 8–14. (In Russ.)] doi: 10.33978/2307-3586-2023-19-32-8-14
- Нестерова И.В. Препараты интерферона альфа в клинической практике // Российский аллергологический журнал. 2010. Т. 7, № 2. C. 43–52. [Nesterova I.V. Interferon-a in clinical practice. Rossiyskiy allergologicheskiy zhurnal = Russian Journal of Allergy, 2010, vol. 7, no. 2, pp. 43–52. (In Russ.)] doi: 10.36691/RJA892
- Нестерова И.В., Халтурина Е.О. Моно- и микст-герпесвирусные инфекции: ассоциированность с клиническими синдромами иммунодефицита // Вестник Российского университета дружбы народов. Серия: Медицина. 2018. Т. 22, № 2. C. 226–234. [Nesterova I.V., Khalturina E.O. Mono- and mixed-herpesvirus infections: association with clinical syndromes of immunodeficiency. Vestnik Rossiiskogo universiteta druzhby narodov. Seriya: Meditsina = RUDN Journal of Medicine, 2018, vol. 22, no. 2, pp. 226–234. (In Russ.)] doi: 10.22363/2313-0245-2018-22-2-226-234
- Нестерова И.В., Чудилова Г.А., Чапурина В.Н., Ковалева С.В., Ломтатидзе Л.В., Тараканов В.А., Тетерин Ю.В., Пирогова А.И. Дифференцированность иммуномодулирующих эффектов аргинил-альфа-аспартил-лизил-валил-тирозил-аргинина и глюкозаминилмурамилдипептида на эффекторные функции и фенотип функционально значимых субпопуляций нейтрофильных гранулоцитов в экспериментальной модели вирусно-бактериальной коинфекции // Иммунология. 2022. Т. 43, № 1. С. 89–102. [Nesterova I.V., Chudilova G.A., Chapurina V.N., Kovaleva S.V., Lomtatidze L.V., Tarakanov V.A., Teterin Yu.V., Pirogova A.I. Differentiation of immunomodulatory effects of arginyl-alpha-aspartyl-lysyl-valyl-tyrosyl-arginine and glucosaminylmuramyldipeptide on effector functions and phenotype of functionally significant subpopulations of neutrophilic granulocytes in an experimental model of viral-bacterial coinfection. Immunologiya = Immunologiya, 2022, vol. 43, no. 1, pp. 89–102. (In Russ.)] doi: 10.33029/0206-4952-2022-43-1-89-102
- Понежева Ж.Б., Купченко А.Н., Маннанова И.В., Горелов А.В. Интерфероны и противовирусный ответ // Эффективная фармакотерапия. Педиатрия. 2018. № 1 (14). С. 14–20. [Ponezheva Zh.B., Kupchenko A.N., Mannanova I.V., Gorelov A.V. Interferons and antiviral immunity. Effektivnaya farmakoterapiya. Pediatrya = Effective Pharmacotherapy. Pediatrics, 2018, no. 1 (14), pp. 14–20. (In Russ.)]
- Свистушкин В.М., Никифорова Г.Н., Левина Л.А., Золотова А.В., Шевчик Е.А. Реальные возможности оптимизации лечения больных аллергическим ринитом // Медицинский Совет. 2022. № 8. С. 98–10⁴. [Svistushkin V.M., Nikiforova G.N., Levina L.А., Zolotova A.V., Shevchik E.A. Real possibilities of treatment of patients with allergic rhinitis. Meditsinskiy sovet = Medical Council, 2022, no. 8, pp. 98–10⁴. (In Russ.)] doi: 10.21518/2079-701X-2022-16-8-98-10⁴
- Татаурщикова Н.С. Особенности аллергического воспаления в оценке фенотипов аллергического ринита // Фарматека. 2018. № s1. C. 12–15. [Tataurshchikova N.S. Features of allergic inflammation in assessment of phenotypes of allergic rhinitis. Farmateka = Pharmateca, 2018, no. s1, pp. 12–15. (In Russ.)] doi: 10.18565/pharmateca.2018.s1.12-15
- Татаурщикова Н.С., Летяева О.И., Максимова А.В., Левкова Е.А. Герпетическая инфекция и аллергия как глобальная проблема современной медицины // Эффективная фармакотерапия. 2023. Т. 19, № 28. С. 24–29. [Tataurshchikova N.S., Letyaeva O.I., Maksimova A.V., Levkova E.A. Herpes infection and allergy as a global problem of modern medicine. Effektivnaya farmakoterapiya = Effective Pharmacotherapy, 2023, vol. 19, no. 28, pp. 24–29. (In Russ.)] doi: 10.33978/2307-3586-2023-19-28-24-29
- Татаурщикова Н.С., Сангидорж Б., Русанова А.С. Локальная иммунотерапия в комплексном лечении пациентов с аллергическим ринитом // Эффективная фармакотерапия. 2022. Т. 18, № 12. С. 28–31. [Tataurshchikova N.S., Sangidorzh B., Rusanova A.S. Local immunotherapy in the complex treatment of patients with allergic rhinitis. Effektivnaya farmakoterapiya = Effective Pharmacotherapy, 2022, vol. 18, no. 12, pp. 28–31. (In Russ.)] doi: 10.17116/otorino201782660-62
- Царев С.В. Инфекция и аллергия: взаимосвязь и взаимовлияние // Русский медицинский журнал. 2016. № 12. С. 800–803. [Tsarev S.V. Infection and allergy: interrelationship and mutual influence. Russkiy meditsinskiy zhurnal = Russian Medical Journal, 2016, no. 12, pp. 800–803. (In Russ.)]
- Baskakova D.V., Haldin A.A., Birko N.I. Clinical and epidemiological characteristics of diseases caused by herpes simplex herpes. Russian Journal of Skin and Sexually Transmitted Diseases. Herpes App., 2006, no. 2, pp. 26–30.
- Fokkens W.J., Lund V., Luong A.U., Orlandi R.R. A Comparison of International Guidelines for Rhinosinusitis. J. Allergy Clin. Immunol. Pract., 2022, vol. 10, no. 6, pp. 1418–1422. doi: 10.1016/j.jaip.2022.01.013
- Global Atlas of Allergic Rhinitis and Chronic Rhinosinusitis. Eds.: Akdis C.A., P.W. Hellings I. Agache. Zurich, Switzerland: European Academy of Allergy and Clinical Immunology, 2015. 422 p.
- Goreiko T.V., Kalinina N.M., Drygina L.V. The modern conceptions about immunopathogenesis of infection caused by the Epstein–Barr virus. Russian Journal of Infection and Immunity, 2011, vol. 1, no. 2, pp. 121–130. doi: 10.15789/2220-7619-2011-2-121-130
- Khalturina E.O., Nesterova I.V., Markova T.P. An optimized program of targeted combined interferon and immunotherapy in the treatment of atypical chronic active herpes virus co-infections. Effective Pharmacotherapy, 2022, vol. 18, no. 1, pp. 44–49.
Supplementary files
